Clinical trial NCT02389933: Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Official title: Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Heart Failure With Reduced Ejection Fraction (HF-rEF)
Keywords: Multiple Patient Program, LCZ696, heart failure, heart failure with reduced ejection fraction, HF-rEF
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2015-03-17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive LCZ696 in their country prior to market authorization OR commercial availability, based on local regulatory and legal requirements.


Eligibility criteria: Inclusion criteria

The patient(s) for whom the MPP is sought meets all of the following:

* Is suffering from a serious or life-threatening disease or condition
* Does not have access to a comparable or satisfactory alternative treatment (i.e., comparable or satisfactory treatment is not available or does not exist)
* Patient should be on optimized standard of care treatment, including treatment with ARBs or ACEI, beta-blockers and MRA;
* Intolerance to evidence-based target doses should be documented by the treating physician
* Meets any other relevant medical criteria for compassionate use of the investigational product

Patients eligible for inclusion in this program have to fulfill all of the following criteria:

1. Adult patients (but not younger than 18 year old) will be included, upon completion of written informed consent before any assessment is performed.
2. Patients with a diagnosis of CHF NYHA class II-IV and reduced ejection fraction:

   • LVEF ≤ 35% at the time of screening for participation in the program (any local measurement, made within the past 6 months using echocardiography, MUGA, CT scanning, MRI or ventricular angiography is acceptable, provided there are no subsequent measurement above 35%)
3. Patient had a hospitalization for HF within the last 12 months
4. Patients must be on an ACEI or an ARB at a stable dose for at least 4 weeks prior to starting treatment with LCZ696
5. Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to starting treatment with LCZ696 (reason should be documented for patients not on CHF target doses per local guidelines, or in absence of that medication).
6. An aldosterone antagonist should also be considered in all patients, taking account of renal function, serum potassium and tolerability. If given, the dose of aldosterone antagonist should be optimized according to guideline recommendations and patient tolerability, and should be stable for at least 4 weeks prior to starting treatment with LCZ696

Exclusion criteria

Patients fulfilling any of the following criteria are not eligible for inclusion in this program:

1. The patient is eligible for participation in any of the IMP's ongoing clinical trials
2. The patient has recently completed a clinical trial that has been terminated and other options (e.g., trial extensions, amendments, etc.) are available to continue a similar treatment.
3. The patient is being transferred from an ongoing clinical trial for which the patient is still eligible for participation
4. History of hypersensitivity or allergy to LCZ696 or to any of its metabolites; to drugs of similar chemical classes, ARBs, or NEP inhibitors; as well as known or suspected contraindications to LCZ696
5. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
6. Previous history of intolerance to recommended target doses of ARBs
7. Known history of angioedema
8. Requirement of concomitant treatment with both ACEIs and ARBs
9. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)
10. Symptomatic hypotension and/or a SBP less than 100 mm Hg over the last 4 weeks prior to starting treatment with LCZ696
11. Estimated GFR below 30 mL/min/1.73m2 as measured by the simplified MDRD formula
12. Presence of bilateral renal artery stenosis
13. Serum potassium above 5.2 mmol/L during the week prior to starting treatment with LCZ696
14. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty within the 3 months prior to starting treatment with LCZ696
15. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after the schedule date to start treatment with LCZ696
16. Implantation of a cardiac resynchronization therapy pacemaker (CRT-P) or a cardiac resynchronization therapy defibrillator (CRT-D) or upgrading of an existing conventional pacemaker or an implantable cardioverter defibrillator (ICD) to CRT device within 3 months prior to starting treatment with LCZ696, or intent to implant such a device.

    Also, patients who had implantation of a conventional pacemaker or an ICD or had a revision of a pacemaker or other device leads within 1 month before starting treatment with LCZ696 are excluded.
17. Heart transplant or ventricular assistance device (VAD) or intent to transplant (on transplant list) or implant a VAD
18. History of severe pulmonary disease
19. Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the 12 months prior to starting treatment with LCZ696
20. Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months prior to starting treatment with LCZ696
21. Symptomatic bradycardia or second or third degree heart block without a pacemaker
22. Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation
23. Presence of other hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis
24. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including but not limited to any of the following:

    * History of active inflammatory bowel disease during the 12 months before starting treatment with LCZ696.
    * Current duodenal or gastric ulcers during the 3 months prior to starting treatment with LCZ696
    * Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x ULN prior to starting treatment with LCZ696, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt
    * Active treatment with cholestyramine or colestipol resins
25. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 3 x ULN prior to starting treatment with LCZ696, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt
26. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (above 5 mIU/mL)
27. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method (if accepted by the local regulatory authority and ethics committee) or a barrier method plus a hormonal method

    * Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progesterone agent.
    * Reliable contraception should be maintained throughout the treatment and for 7 days after LCZ696 treatment discontinuation
    * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea, or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
28. Presence of any other disease with a life expectancy of \< 3 years
29. Any condition, not identified in the protocol that in the opinion of the treating physician is likely to prevent the patient from safely tolerating LCZ696 or complying with the requirements of the therapy.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vero Beach
country: United States
facility: Novartis Investigative Site
state: Florida
city: Darlinghurst
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: North Ryde
country: Australia
facility: Novartis Investigative Site
state: New South Wales
city: Perth
country: Australia
facility: Novartis Investigative Site
state: Western Australia
city: Krems
country: Austria
facility: Novartis Investigative Site
city: Salzburg
country: Austria
facility: Novartis Investigative Site
city: St. Poelten
country: Austria
facility: Novartis Investigative Site
city: Vienna
country: Austria
facility: Novartis Investigative Site
city: Wien
country: Austria
facility: Novartis Investigative Site
city: Salvador
country: Brazil
facility: Novartis Investigative Site
state: BA
city: Fortaleza
country: Brazil
facility: Novartis Investigative Site
state: CE
city: Belo Horizonte
country: Brazil
facility: Novartis Investigative Site
state: MG
city: Porto Alegre
country: Brazil
facility: Novartis Investigative Site
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
facility: Novartis Investigative Site
state: RS
city: Varazdin
country: Croatia
facility: Novartis Investigative Site
state: HRV
city: Limassol
country: Cyprus
facility: Novartis Investigative Site
city: Nicosia
country: Cyprus
facility: Novartis Investigative Site
city: Nicosia
country: Cyprus
facility: Novartis Investigative Site
city: Nicosia
country: Cyprus
facility: Novartis Investigative Site
city: Nicosia
country: Cyprus
facility: Novartis Investigative Site
city: Nicosia
country: Cyprus
facility: Novartis Investigative Site
city: Marseille cedex 20
country: France
facility: Novartis Investigative Site
state: Bouches Du Rhone
city: Bron
country: France
facility: Novartis Investigative Site
state: Cedex
city: Caen
country: France
facility: Novartis Investigative Site
state: Cedex
city: Saint Denis
country: France
facility: Novartis Investigative Site
state: France / La Reunion
city: Amiens cedex 1
country: France
facility: Novartis Investigative Site
city: Amilly
country: France
facility: Novartis Investigative Site
city: Angers Cedex 9
country: France
facility: Novartis Investigative Site
city: Antibes
country: France
facility: Novartis Investigative Site
city: Aressy
country: France
facility: Novartis Investigative Site
city: Avignon Cedex 2
country: France
facility: Novartis Investigative Site
city: Avignon
country: France
facility: Novartis Investigative Site
city: Bayeux
country: France
facility: Novartis Investigative Site
city: Beziers Cedex
country: France
facility: Novartis Investigative Site
city: Bobigny
country: France
facility: Novartis Investigative Site
city: Brest Armees
country: France
facility: Novartis Investigative Site
city: Brest
country: France
facility: Novartis Investigative Site
city: Bron Cedex
country: France
facility: Novartis Investigative Site
city: Bron
country: France
facility: Novartis Investigative Site
city: Caen Cedex
country: France
facility: Novartis Investigative Site
city: Caen
country: France
facility: Novartis Investigative Site
city: Cambrai Cedex
country: France
facility: Novartis Investigative Site
city: Cannes Cedex
country: France
facility: Novartis Investigative Site
city: Chambéry cedex
country: France
facility: Novartis Investigative Site
city: Chaumont Cedex
country: France
facility: Novartis Investigative Site
city: Cherbourg Octeville
country: France
facility: Novartis Investigative Site
city: Clamart
country: France
facility: Novartis Investigative Site
city: Clermont-Ferrand cedex 1
country: France
facility: Novartis Investigative Site
city: Compiègne cedex
country: France
facility: Novartis Investigative Site
city: Contamine Sur Arve
country: France
facility: Novartis Investigative Site
city: Corbeil Essonnes
country: France
facility: Novartis Investigative Site
city: Cornebarrieu
country: France
facility: Novartis Investigative Site
city: Dijon
country: France
facility: Novartis Investigative Site
city: Eaubonne
country: France
facility: Novartis Investigative Site
city: Honfleur Cedex
country: France
facility: Novartis Investigative Site
city: Hyeres
country: France
facility: Novartis Investigative Site
city: La Roche sur Yon Cedex
country: France
facility: Novartis Investigative Site
city: La Seyne sur mer
country: France
facility: Novartis Investigative Site
city: La Tronche
country: France
facility: Novartis Investigative Site
city: Lille Cedex
country: France
facility: Novartis Investigative Site
city: Lille Cedex
country: France
facility: Novartis Investigative Site
city: Limoges
country: France
facility: Novartis Investigative Site
city: Lyon CEDEX 04
country: France
facility: Novartis Investigative Site
city: Lyon
country: France
facility: Novartis Investigative Site
city: Lyon
country: France
facility: Novartis Investigative Site
city: Marseille Cedex 05
country: France
facility: Novartis Investigative Site
city: Marseille Cedex 20
country: France
facility: Novartis Investigative Site
city: Marseille
country: France
facility: Novartis Investigative Site
city: Marseille
country: France
facility: Novartis Investigative Site
city: Metz Cedex
country: France
facility: Novartis Investigative Site
city: Metz-Tessy
country: France
facility: Novartis Investigative Site
city: Monaco
country: France
facility: Novartis Investigative Site
city: Montbeliard Cedex
country: France
facility: Novartis Investigative Site
city: Montpellier Cedex
country: France
facility: Novartis Investigative Site
city: Montpellier
country: France
facility: Novartis Investigative Site
city: Morlaix Cedex
country: France
facility: Novartis Investigative Site
city: Moulins Cedex
country: France
facility: Novartis Investigative Site
city: Mulhouse Cedex
country: France
facility: Novartis Investigative Site
city: Mâcon Cedex
country: France
facility: Novartis Investigative Site
city: Nantes Cedex 1
country: France
facility: Novartis Investigative Site
city: Neuilly-sur-seine
country: France
facility: Novartis Investigative Site
city: Nice Cedex 1
country: France
facility: Novartis Investigative Site
city: Nice Cedex 2
country: France
facility: Novartis Investigative Site
city: Nimes
country: France
facility: Novartis Investigative Site
city: Paris Cedex 10
country: France
facility: Novartis Investigative Site
city: Paris Cedex 13
country: France
facility: Novartis Investigative Site
city: Paris Cedex 14
country: France
facility: Novartis Investigative Site
city: Pau Cedex
country: France
facility: Novartis Investigative Site
city: Perpignan
country: France
facility: Novartis Investigative Site
city: Pessac Cedex
country: France
facility: Novartis Investigative Site
city: Poitiers
country: France
facility: Novartis Investigative Site
city: Pont L'Abbe
country: France
facility: Novartis Investigative Site
city: Pontarlier Cedex
country: France
facility: Novartis Investigative Site
city: Pontoise
country: France
facility: Novartis Investigative Site
city: Rennes Cedex 9
country: France
facility: Novartis Investigative Site
city: Rouen Cedex
country: France
facility: Novartis Investigative Site
city: Rumilly
country: France
facility: Novartis Investigative Site
city: Saint Denis
country: France
facility: Novartis Investigative Site
city: Saint Denis
country: France
facility: Novartis Investigative Site
city: Saint Etienne Cedex 2
country: France
facility: Novartis Investigative Site
city: Saint Palais
country: France
facility: Novartis Investigative Site
city: Saint-Germain-en-Laye
country: France
facility: Novartis Investigative Site
city: St Jean
country: France
facility: Novartis Investigative Site
city: St. Etienne
country: France
facility: Novartis Investigative Site
city: Strasbourg
country: France
facility: Novartis Investigative Site
city: Thonon Les Bains Cedex
country: France
facility: Novartis Investigative Site
city: Toulouse Cedex
country: France
facility: Novartis Investigative Site
city: Toulouse
country: France
facility: Novartis Investigative Site
city: Tours
country: France
facility: Novartis Investigative Site
city: Valence Cedex 9
country: France
facility: Novartis Investigative Site
city: Valenciennes Cedex
country: France
facility: Novartis Investigative Site
city: Vandoeuvre Les Nancy
country: France
facility: Novartis Investigative Site
city: Vichy
country: France
facility: Novartis Investigative Site
city: Villefranche sur Saone
country: France
facility: Novartis Investigative Site
city: Wattrelos
country: France
facility: Novartis Investigative Site
city: Suderholz
country: Germany
facility: Novartis Investigative Site
state: OT Bartmannshagen
city: Ahlen
country: Germany
facility: Novartis Investigative Site
city: Augsburg
country: Germany
facility: Novartis Investigative Site
city: Bad Endbach
country: Germany
facility: Novartis Investigative Site
city: Bad Homburg
country: Germany
facility: Novartis Investigative Site
city: Bad Kreuznach
country: Germany
facility: Novartis Investigative Site
city: Bad Krozingen
country: Germany
facility: Novartis Investigative Site
city: Bad Oeynhausen
country: Germany
facility: Novartis Investigative Site
city: Berlin
country: Germany
facility: Novartis Investigative Site
city: Berlin
country: Germany
facility: Novartis Investigative Site
city: Bielefeld
country: Germany
facility: Novartis Investigative Site
city: Bielefeld
country: Germany
facility: Novartis Investigative Site
city: Bonn
country: Germany
facility: Novartis Investigative Site
city: Chemnitz
country: Germany
facility: Novartis Investigative Site
city: Chemnitz
country: Germany
facility: Novartis Investigative Site
city: Chemnitz
country: Germany
facility: Novartis Investigative Site
city: Cologne
country: Germany
facility: Novartis Investigative Site
city: Dessau-Rosslau
country: Germany
facility: Novartis Investigative Site
city: Diepholz
country: Germany
facility: Novartis Investigative Site
city: Dinslaken
country: Germany
facility: Novartis Investigative Site
city: Dortmund
country: Germany
facility: Novartis Investigative Site
city: Dresden
country: Germany
facility: Novartis Investigative Site
city: Dresden
country: Germany
facility: Novartis Investigative Site
city: Dresden
country: Germany
facility: Novartis Investigative Site
city: Dusseldorf
country: Germany
facility: Novartis Investigative Site
city: Eilenburg
country: Germany
facility: Novartis Investigative Site
city: Eschwege
country: Germany
facility: Novartis Investigative Site
city: Essen
country: Germany
facility: Novartis Investigative Site
city: Frankfurt
country: Germany
facility: Novartis Investigative Site
city: Frankfurt
country: Germany
facility: Novartis Investigative Site
city: Frankfurt
country: Germany
facility: Novartis Investigative Site
city: Frankfurt
country: Germany
facility: Novartis Investigative Site
city: Friedrichroda
country: Germany
facility: Novartis Investigative Site
city: Goettingen
country: Germany
facility: Novartis Investigative Site
city: Gronau
country: Germany
facility: Novartis Investigative Site
city: Guenzburg
country: Germany
facility: Novartis Investigative Site
city: Hamburg
country: Germany
facility: Novartis Investigative Site
city: Hannover
country: Germany
facility: Novartis Investigative Site
city: Hannover
country: Germany
facility: Novartis Investigative Site
city: Hassfurt
country: Germany
facility: Novartis Investigative Site
city: Hassloch
country: Germany
facility: Novartis Investigative Site
city: Hohenstein-Ernstthal
country: Germany
facility: Novartis Investigative Site
city: Jena
country: Germany
facility: Novartis Investigative Site
city: Karlsruhe
country: Germany
facility: Novartis Investigative Site
city: Kassel
country: Germany
facility: Novartis Investigative Site
city: Koeln
country: Germany
facility: Novartis Investigative Site
city: Koeln
country: Germany
facility: Novartis Investigative Site
city: Köthen
country: Germany
facility: Novartis Investigative Site
city: Lauchringen
country: Germany
facility: Novartis Investigative Site
city: Leipzig
country: Germany
facility: Novartis Investigative Site
city: Ludwigshafen
country: Germany
facility: Novartis Investigative Site
city: Magdeburg
country: Germany
facility: Novartis Investigative Site
city: Magdeburg
country: Germany
facility: Novartis Investigative Site
city: Mainz
country: Germany
facility: Novartis Investigative Site
city: Mannheim
country: Germany
facility: Novartis Investigative Site
city: Marl
country: Germany
facility: Novartis Investigative Site
city: Muenchen
country: Germany
facility: Novartis Investigative Site
city: Munchen
country: Germany
facility: Novartis Investigative Site
city: Munster
country: Germany
facility: Novartis Investigative Site
city: Oldenburg
country: Germany
facility: Novartis Investigative Site
city: Pressath
country: Germany
facility: Novartis Investigative Site
city: Rostock
country: Germany
facility: Novartis Investigative Site
city: Ulm
country: Germany
facility: Novartis Investigative Site
city: Weinheim
country: Germany
facility: Novartis Investigative Site
city: Wildeshausen
country: Germany
facility: Novartis Investigative Site
city: Wolfratshausen
country: Germany
facility: Novartis Investigative Site
city: Wuerzburg
country: Germany
facility: Novartis Investigative Site
city: Alexandroupolis
country: Greece
facility: Novartis Investigative Site
state: Evros
city: Athens
country: Greece
facility: Novartis Investigative Site
state: GR
city: Athens
country: Greece
facility: Novartis Investigative Site
state: GR
city: Athens
country: Greece
facility: Novartis Investigative Site
state: GR
city: Athens
country: Greece
facility: Novartis Investigative Site
state: GR
city: Ioannina
country: Greece
facility: Novartis Investigative Site
state: GR
city: Larissa
country: Greece
facility: Novartis Investigative Site
state: GR
city: Thessaloniki
country: Greece
facility: Novartis Investigative Site
state: GR
city: Thessaloniki
country: Greece
facility: Novartis Investigative Site
state: GR
city: Thessaloniki
country: Greece
facility: Novartis Investigative Site
state: GR
city: Tripoli
country: Greece
facility: Novartis Investigative Site
state: GR
city: Voula
country: Greece
facility: Novartis Investigative Site
state: GR
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Athens
country: Greece
facility: Novartis Investigative Site
city: Chaidari
country: Greece
facility: Novartis Investigative Site
city: Chios
country: Greece
facility: Novartis Investigative Site
city: Edessa
country: Greece
facility: Novartis Investigative Site
city: Elefsina
country: Greece
facility: Novartis Investigative Site
city: Glyfada
country: Greece
facility: Novartis Investigative Site
city: Heraklion - Crete
country: Greece
facility: Novartis Investigative Site
city: Heraklion
country: Greece
facility: Novartis Investigative Site
city: Ioannina
country: Greece
facility: Novartis Investigative Site
city: Kalamata
country: Greece
facility: Novartis Investigative Site
city: Karditsa
country: Greece
facility: Novartis Investigative Site
city: Katerini
country: Greece
facility: Novartis Investigative Site
city: Kavala
country: Greece
facility: Novartis Investigative Site
city: Kerkyra
country: Greece
facility: Novartis Investigative Site
city: Kilkis
country: Greece
facility: Novartis Investigative Site
city: Kozani
country: Greece
facility: Novartis Investigative Site
city: Maroussi
country: Greece
facility: Novartis Investigative Site
city: Piraeus
country: Greece
facility: Novartis Investigative Site
city: Piraeus
country: Greece
facility: Novartis Investigative Site
city: Rio Patra
country: Greece
facility: Novartis Investigative Site
city: Thesaloniki
country: Greece
facility: Novartis Investigative Site
city: Thessaloniki
country: Greece
facility: Novartis Investigative Site
city: Thessaloniki
country: Greece
facility: Novartis Investigative Site
city: Thessaloniki
country: Greece
facility: Novartis Investigative Site
city: Volos
country: Greece
facility: Novartis Investigative Site
city: Co Dublin
country: Ireland
facility: Novartis Investigative Site
city: Dublin
country: Ireland
facility: Novartis Investigative Site
city: Ashrafieh
country: Lebanon
facility: Novartis Investigative Site
city: Beirut
country: Lebanon
facility: Novartis Investigative Site
city: Beirut
country: Lebanon
facility: Novartis Investigative Site
city: Beirut
country: Lebanon
facility: Novartis Investigative Site
city: Beirut
country: Lebanon
facility: Novartis Investigative Site
city: Beirut
country: Lebanon
facility: Novartis Investigative Site
city: Beirut
country: Lebanon
facility: Novartis Investigative Site
city: Saida
country: Lebanon
facility: Novartis Investigative Site
city: Tripoli
country: Lebanon
facility: Novartis Investigative Site
city: Msida
country: Malta
facility: Novartis Investigative Site
city: Panama City
country: Panama
facility: Novartis Investigative Site
city: Panama
country: Panama
facility: Novartis Investigative Site
city: Manila
country: Philippines
facility: Novartis Investigative Site
state: Metro Manila
city: Makati City
country: Philippines
facility: Novartis Investigative Site
city: Manila
country: Philippines
facility: Novartis Investigative Site
city: Ljubljana
country: Slovenia
facility: Novartis Investigative Site
city: Cordoba
country: Spain
facility: Novartis Investigative Site
state: Andalucia
city: Garanada
country: Spain
facility: Novartis Investigative Site
state: Andalucia
city: Jerez de la Frontera
country: Spain
facility: Novartis Investigative Site
state: Andalucia
city: Sevilla
country: Spain
facility: Novartis Investigative Site
state: Andalucia
city: Utrera
country: Spain
facility: Novartis Investigative Site
state: Andalucia
city: Hospitalet de Llobregat
country: Spain
facility: Novartis Investigative Site
state: Barcelona
city: Villamartin
country: Spain
facility: Novartis Investigative Site
state: Cadiz
city: Santander
country: Spain
facility: Novartis Investigative Site
state: Cantabria
city: Torrelavega
country: Spain
facility: Novartis Investigative Site
state: Cantabria
city: Lleida
country: Spain
facility: Novartis Investigative Site
state: Cataluna
city: Barcelona
country: Spain
facility: Novartis Investigative Site
state: Catalunya
city: Salt
country: Spain
facility: Novartis Investigative Site
state: Cataluña
city: Badajoz
country: Spain
facility: Novartis Investigative Site
state: Extremadura
city: Pontevedra
country: Spain
facility: Novartis Investigative Site
state: Galicia
city: Logrono
country: Spain
facility: Novartis Investigative Site
state: La Rioja
city: Las Palmas de Gran Canaria
country: Spain
facility: Novartis Investigative Site
state: Las Palmas De G.C
city: Majadahonda
country: Spain
facility: Novartis Investigative Site
state: Madrid
city: San Sebastian de los Reyes
country: Spain
facility: Novartis Investigative Site
state: Madrid
city: San Sebastian de los Reyes
country: Spain
facility: Novartis Investigative Site
state: Madrid
city: Marbella
country: Spain
facility: Novartis Investigative Site
state: Malaga
city: Pamplona
country: Spain
facility: Novartis Investigative Site
state: Navarra
city: Bilbao
country: Spain
facility: Novartis Investigative Site
state: Pais Vasco
city: Galdakano
country: Spain
facility: Novartis Investigative Site
state: Pais Vasco
city: Badalona
country: Spain
facility: Novartis Investigative Site
city: Baleares
country: Spain
facility: Novartis Investigative Site
city: El Palmar (Murcia)
country: Spain
facility: Novartis Investigative Site
city: Las Palmas de Gran Canaria
country: Spain
facility: Novartis Investigative Site
city: Las Palmas de Gran Canaria
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Madrid
country: Spain
facility: Novartis Investigative Site
city: Salamanca
country: Spain
facility: Novartis Investigative Site
city: Sevilla
country: Spain
facility: Novartis Investigative Site
city: Sevilla
country: Spain
facility: Novartis Investigative Site
city: Zaragoza
country: Spain
facility: Novartis Investigative Site
city: Zaragoza
country: Spain
facility: Novartis Investigative Site
city: Luzern
country: Switzerland
facility: Novartis Investigative Site
state: LU
city: Abu Dhabi
country: United Arab Emirates
facility: Novartis Investigative Site
city: Ras Al Khaimah
country: United Arab Emirates
facility: Novartis Investigative Site
Study officials:
References: